Abstract Submission

ESPACOMP 2022: call for late-breaking abstracts is open

Dear Colleagues,

Following several inquiries by members, ESPACOMP is opening this year a Call for Late-breaking Abstracts. We have already received over 90 abstracts and we are currently communicating results of abstract reviewing to authors. The scientific programme will be available soon on the ESPACOMP website and we are looking forward to a hybrid event showcasing a diverse range of oral and poster presentations.

We invite you to submit abstracts presenting new information that was not fully available by the regular abstract submission deadline, July 15^th. As for the regular call for abstracts, we welcome submissions on all aspects of medication adherence research (e.g. intervention research, observational studies, implementation science, measurement studies, policy evaluation).

The deadline for abstract submission is 11:59pm (CET) August 31, 2022. Submitted abstracts will be scored by reviewers, and decisions on their acceptance as poster presentations will be communicated by mid-September.

The 26th ESPACOMP Conference will be held in a hybrid format from November 17^th to 19^th 2022 in Berlin, Germany. It will have a special focus on Adherence and Patient Safety. Information about online and in person participation will be made available soon on the society website and social media: on LinkedIn (in “Groups” search for “ESPACOMP’) or on Twitter (@SocMedAdherence).

Accepted and presented abstracts will be published in International Journal of Clinical Pharmacy.

Abstract Format:

Abstracts must be structured, with section headings for Aim, Methods, Results, Discussion, and Conclusion
Abstracts must be limited to 250 words, including the title
Abstracts must adopt the ESPACOMP-endorsed ABC Taxonomy, available here
Authors must present in the abstract, in as much detail as space permits, information on the 4 minimum reporting criteria outlined in the ESPACOMP EMERGE reporting guidelines. These are available here

Additional information about the meeting program will be posted at www.espacomp.eu when it is available.

Specific questions about the ESPACOMP conference may be directed to info@espacomp.eu.

Your Name (required)

Your Email (required)

Abstract Title ( Maximum of 15 words describing the research) (required)

words. Please limit to 15 words or less With Space.

Authors. The first author should be the person who contributed most to the work, including writing of the abstract. The last author is usually a senior author (e.g. supervisor) and guarantor who accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to submit.

Institutional Affiliations and Countries

Is the first/presenting author a doctoral student?

Is the first/presenting author a post-doc or within 5 years of completing their PhD or doctoral degree?

Content.
The introduction, aim, methods, results, discussion and conclusion sections must be within the 235 word limit .
Most words should be dedicated to the methods and results sections.
Authors must adopt the ESPACOMP endorsed ABC taxonomy

Authors must present in the abstract, in as much detail as space permits, information on the 4 minimum reporting criteria report according to the ESPACOMP EMERGE reporting guidelines

Introduction - Aim - Methods - Results - Discussion - Conclusion
words. Please limit to 235 words or less With Space.

Due to copyright restrictions, the abstracts accepted for presentation at ESPACOMP that have been previously presented at other conferences, or already published, can not be accepted for publication in the International Journal of Clinical Pharmacy. Has this work been previously presented or published?
yesno